| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Maytansinoids
DM1-SMe is a potent maytansinoid microtubular inhibitor. It is an unconjugated form of the maytansinoid used in antibody-drug conjugates (ADCs). The compound can be readily conjugated to the SH group of an antibody to form an ADC. DM1-SMe targets microtubules, disrupting cell division. |
|---|---|
| ln Vitro |
In vitro, DM1-SMe is a potent microtubular inhibitor that disrupts tubulin polymerization and causes cell cycle arrest. It exhibits potent cytotoxicity against various cancer cell lines. Structure-activity-relationship studies have identified the C3 ester side chain as critical for activity. The compound is used as the cytotoxic payload in ADC development.
|
| ln Vivo |
In vivo, DM1-SMe is used as the active cytotoxic component in antibody-drug conjugates. Following antibody-mediated delivery to tumor cells, the compound inhibits microtubule dynamics, leading to mitotic arrest and apoptosis. DM1-SMe has demonstrated antitumor efficacy in xenograft models when conjugated to tumor-targeting antibodies. It is the unconjugated form of the maytansinoid in IMGN901.
|
| Enzyme Assay |
In vitro receptor/enzyme binding assays for DM1-SMe typically involve studying its interaction with tubulin. The compound's ability to inhibit tubulin polymerization is measured using spectrophotometric assays that track microtubule assembly. Binding affinity for tubulin is determined using fluorescence-based or surface plasmon resonance methods. The compound's potency as a microtubule inhibitor is quantified by IC50 values for tubulin polymerization inhibition.
|
| Cell Assay |
Cell-based cytotoxicity assays for DM1-SMe involve treating various cancer cell lines with increasing concentrations of the compound. Cell viability is assessed after 48-72 hours using MTT, CellTiter-Glo, or clonogenic assays. IC50 values are calculated from dose-response curves. The mechanism of cell death (apoptosis vs. necrosis) is evaluated by caspase activation, Annexin V staining, and cell cycle analysis. The compound's potency is compared to other maytansinoids.
|
| Animal Protocol |
In vivo animal studies for DM1-SMe typically involve administering the compound as an ADC conjugate to mice bearing human tumor xenografts. The ADC is administered intravenously at various doses, and tumor growth inhibition is monitored over several weeks. Pharmacodynamic endpoints include tumor volume, weight, and histology. Survival is also assessed. The unconjugated DM1-SMe may be used as a control to demonstrate antibody-targeted delivery.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of DM1-SMe are characteristic of maytansinoid payloads. When administered as an unconjugated compound, it has a short half-life and rapid clearance. As part of an ADC, the compound is delivered specifically to tumor cells, with limited systemic exposure. The disulfide bond can be cleaved intracellularly to release the active DM1 species. Metabolism occurs primarily in the liver.
|
| Toxicity/Toxicokinetics |
Toxicological profile of DM1-SMe is consistent with potent microtubule inhibitors. The compound can cause significant cytotoxicity, particularly to rapidly dividing cells. Common toxicities include myelosuppression, gastrointestinal effects, and neuropathy. When delivered as an ADC, toxicity is reduced due to targeted delivery. The compound should be handled with caution in laboratory settings.
|
| References |
|
| Additional Infomation |
DM1-SMe is a key research tool for antibody-drug conjugate development. It serves as the cytotoxic payload in several clinically approved ADCs, including trastuzumab emtansine (Kadcyla). The compound is used to study microtubule inhibition, ADC design, and targeted cancer therapy. Its well-characterized pharmacology makes it a reference standard for ADC payload development.
|
| Molecular Formula |
C36H50CLN3O10S2
|
|---|---|
| Molecular Weight |
784.377
|
| Exact Mass |
783.263
|
| Elemental Analysis |
C, 55.13; H, 6.43; Cl, 4.52; N, 5.36; O, 20.40; S, 8.17
|
| CAS # |
138148-68-2
|
| Related CAS # |
138148-68-2
|
| PubChem CID |
11650734
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.309
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
52
|
| Complexity |
1370
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CSSCCC(N(C)[C@@H](C)C(O[C@@H]1[C@@]2(O[C@H]2[C@H](C)[C@H]2OC(N[C@](O)(C2)[C@H](OC)C=CC=C(C)CC2C=C(OC)C(Cl)=C(C=2)N(C)C(=O)C1)=O)C)=O)=O |t:30,32,37,&1:8,12,13,15,16,18,22,25|
|
| InChi Key |
ZLUUPZXOPGORNG-UDXCHANISA-N
|
| InChi Code |
InChI=1S/C36H50ClN3O10S2/c1-20-11-10-12-27(47-8)36(45)19-26(48-34(44)38-36)21(2)32-35(4,50-32)28(49-33(43)22(3)39(5)29(41)13-14-52-51-9)18-30(42)40(6)24-16-23(15-20)17-25(46-7)31(24)37/h10-12,16-17,21-22,26-28,32,45H,13-15,18-19H2,1-9H3,(H,38,44)/b12-10-,20-11-/t21-,22+,26+,27-,28+,32+,35+,36+/m1/s1
|
| Chemical Name |
[(1S,2R,3S,5S,6S,16Z,18Z,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] (2S)-2-[methyl-[3-(methyldisulfanyl)propanoyl]amino]propanoate
|
| Synonyms |
DM1-SMe; SMe-DM4; mDM1-SSMe; Maytansine or mertansine or emtansine derivative; aytansinoid derivative with ADC linker; N2'-deacetyl-N2'-[3-(methyldithio)-1-oxopropyl]maytansine.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~127.5 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.19 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2749 mL | 6.3745 mL | 12.7489 mL | |
| 5 mM | 0.2550 mL | 1.2749 mL | 2.5498 mL | |
| 10 mM | 0.1275 mL | 0.6374 mL | 1.2749 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
